172 related articles for article (PubMed ID: 37972336)
1. Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency.
Stecklein SR; Barlow W; Pusztai L; Timms K; Kennedy R; Logan GE; Seitz R; Badve S; Gökmen-Polar Y; Porter P; Linden H; Tripathy D; Hortobagyi GN; Godwin AK; Thompson A; Hayes DF; Sharma P
JCO Precis Oncol; 2023 Sep; 7():e2300197. PubMed ID: 37972336
[TBL] [Abstract][Full Text] [Related]
2. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
[TBL] [Abstract][Full Text] [Related]
3. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313).
Sharma P; Barlow WE; Godwin AK; Pathak H; Isakova K; Williams D; Timms KM; Hartman AR; Wenstrup RJ; Linden HM; Tripathy D; Hortobagyi GN; Hayes DF
Ann Oncol; 2018 Mar; 29(3):654-660. PubMed ID: 29293876
[TBL] [Abstract][Full Text] [Related]
4. Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer.
Liao G; Jiang Z; Yang Y; Zhang C; Jiang M; Zhu J; Xu L; Xie A; Yan M; Zhang Y; Xiao Y; Li X
BMC Med; 2021 Sep; 19(1):190. PubMed ID: 34465315
[TBL] [Abstract][Full Text] [Related]
5. Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T; Kitano S; Masuda N; Ikarashi D; Yamashita M; Chiba T; Kadoya T; Bando H; Yamanaka T; Ohtani S; Nagai S; Nakayama T; Takahashi M; Saji S; Aogi K; Velaga R; Kawaguchi K; Morita S; Haga H; Ohno S; Toi M
BMC Med; 2022 Apr; 20(1):136. PubMed ID: 35462552
[TBL] [Abstract][Full Text] [Related]
6. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
7. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
8. A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer.
Su GH; Jiang L; Xiao Y; Zheng RC; Wang H; Jiang YZ; Peng WJ; Shao ZM; Gu YJ; You C
Ann Surg Oncol; 2022 Oct; 29(11):7165-7175. PubMed ID: 35711018
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological analysis of homologous recombination-deficient breast cancers with special reference to response to neoadjuvant paclitaxel followed by FEC.
Imanishi S; Naoi Y; Shimazu K; Shimoda M; Kagara N; Tanei T; Miyake T; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2019 Apr; 174(3):627-637. PubMed ID: 30607631
[TBL] [Abstract][Full Text] [Related]
10. Homologous recombination deficiency in triple-negative breast cancer: Multi-scale transcriptomics reveals distinct tumor microenvironments and limitations in predicting immunotherapy response.
Kang K; Wu Y; Han C; Wang L; Wang Z; Zhao A
Comput Biol Med; 2023 May; 158():106836. PubMed ID: 37031511
[TBL] [Abstract][Full Text] [Related]
11. Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
Ding JH; Xiao Y; Yang F; Song XQ; Xu Y; Ding XH; Ding R; Shao ZM; Di GH; Jiang YZ
Sci Transl Med; 2024 Jan; 16(728):eadg7740. PubMed ID: 38170790
[TBL] [Abstract][Full Text] [Related]
12. Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
Llop-Guevara A; Loibl S; Villacampa G; Vladimirova V; Schneeweiss A; Karn T; Zahm DM; Herencia-Ropero A; Jank P; van Mackelenbergh M; Fasching PA; Marmé F; Stickeler E; Schem C; Dienstmann R; Florian S; Nekljudova V; Balmaña J; Hahnen E; Denkert C; Serra V
Ann Oncol; 2021 Dec; 32(12):1590-1596. PubMed ID: 34520831
[TBL] [Abstract][Full Text] [Related]
13. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
14. Association between homologous recombination deficiency and outcomes with platinum and platinum-free chemotherapy in patients with triple-negative breast cancer.
Chen Y; Wang X; Du F; Yue J; Si Y; Zhao X; Cui L; Zhang B; Bei T; Xu B; Yuan P
Cancer Biol Med; 2023 Mar; 20(2):155-68. PubMed ID: 36861447
[TBL] [Abstract][Full Text] [Related]
15. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto.
Loibl S; Weber KE; Timms KM; Elkin EP; Hahnen E; Fasching PA; Lederer B; Denkert C; Schneeweiss A; Braun S; Salat CT; Rezai M; Blohmer JU; Zahm DM; Jackisch C; Gerber B; Klare P; Kümmel S; Schem C; Paepke S; Schmutzler R; Rhiem K; Penn S; Reid J; Nekljudova V; Hartman AR; von Minckwitz G; Untch M
Ann Oncol; 2018 Dec; 29(12):2341-2347. PubMed ID: 30335131
[TBL] [Abstract][Full Text] [Related]
16. TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker.
Mayer EL; Abramson V; Jankowitz R; Falkson C; Marcom PK; Traina T; Carey L; Rimawi M; Specht J; Miller K; Stearns V; Tung N; Perou C; Richardson AL; Componeschi K; Trippa L; Tan-Wasielewski Z; Timms K; Krop I; Wolff AC; Winer EP
Ann Oncol; 2020 Nov; 31(11):1518-1525. PubMed ID: 32798689
[TBL] [Abstract][Full Text] [Related]
17. Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and
Telli ML; Chu C; Badve SS; Vinayak S; Silver DP; Isakoff SJ; Kaklamani V; Gradishar W; Stearns V; Connolly RM; Ford JM; Gruber JJ; Adams S; Garber J; Tung N; Neff C; Bernhisel R; Timms KM; Richardson AL
Clin Cancer Res; 2020 Jun; 26(11):2704-2710. PubMed ID: 31796517
[TBL] [Abstract][Full Text] [Related]
18. Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer.
Yndestad S; Engebrethsen C; Herencia-Ropero A; Nikolaienko O; Vintermyr OK; Lillestøl RK; Minsaas L; Leirvaag B; Iversen GT; Gilje B; Blix ES; Espelid H; Lundgren S; Geisler J; Aase HS; Aas T; Gudlaugsson EG; Llop-Guevara A; Serra V; Janssen EAM; Lønning PE; Knappskog S; Eikesdal HP
JCO Precis Oncol; 2023 Sep; 7():e2300338. PubMed ID: 38039432
[TBL] [Abstract][Full Text] [Related]
19. Homologous recombination deficiency in triple negative breast cancer.
Belli C; Duso BA; Ferraro E; Curigliano G
Breast; 2019 Jun; 45():15-21. PubMed ID: 30818144
[TBL] [Abstract][Full Text] [Related]
20. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
